Cardiovascular morbidity in long-term survivors of metastatic testicular cancer

Journal of Clinical Oncology

Volumn 18, Issue 8, 2000, Pages 1725-1732

  Meinardi, M T ^a   Gietema, J A ^a   van der Graaf, W T A ^a   van Veldhuisen, D J ^a   Runne, M A ^a   Sluiter, W J ^a   de Vries, E G E ^a   Willemse, P B H ^a   Mulder, N H ^a   van den Berg, M P ^a   Schraffordt Koops, H ^a   Sleijfer, D Th ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MICROALBUMINURIA; ORCHIECTOMY; PRIORITY JOURNAL; RISK FACTOR; TESTIS CANCER;

EID: 17644431109     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.8.1725     Document Type: Article

References (54)

1. Fossa SD, Lehne G, Heimdal K, et al: Clinical and biochemical long-term toxicity after postoperative cisplatin-based chemotherapy in patients with low-stage testicular cancer. Oncology 52:300-305, 1995
2. Stoter G, Koopman A, Vendrik CP, et al: Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin. J Clin Oncol 7:1099-1104, 1989
3. Stuart NSA, Woodroffe CM, Grundy R, et al: Long-term toxicity of chemotherapy for testicular cancer: The cost of cure. Br J Cancer 61:479-484, 1990
4. Samuels BL, Vogelzang NJ, Kennedy BJ: Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy. Cancer Chemother Pharmacol 19:253-256, 1987
5. Doll DC, List AF, Greco FA, et al: Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med 105:48-51, 1986
6. Gietema JA, Sleijfer DT, Willemse PHB, et al: Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer. Ann Intern Med 116:709-715, 1992
7. Boyer M, Raghavan D, Harris PJ, et al: Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer. J Clin Oncol 8:21-26, 1990
8. Raghavan D, Cox K, Childs A, et al: Hypercholesterolemia after chemotherapy for testis cancer. J Clin Oncol 10:1386-1389, 1992
9. Bokemeyer C, Berger CC, Kuczyk MA, et al: Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 14:2923-2932, 1996
10. Berger CC, Bokemeyer C, Schneider M, et al: Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer 31A:2229-2238, 1995
11. Bissett D, Kunkeler L, Zwanenburg L, et al: Long-term sequelae of treatment for testicular germ cell tumours. Br J Cancer 62:655-659, 1990
12. Hansen SW, Olsen N: Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin for germ cell cancer: Measurement of vasoconstrictor response to cold. J Clin Oncol 7:940-942, 1989
13. Volksgezondheid Toekomst Verkenning: De gezondheidstoestand: Een actualisering-Bilthoven, the Netherlands, National Institute of Public Health and Environmental Protection. Maarssen, the Netherlands, Elsevier/De Tijdstroom, 1997
14. de Wit R, Stoter G, Sleijfer DT, et al: Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma: A randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer 71:1311-1314, 1995
15. de Wit R, Stoter G, Kaye SB, et al: Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 15:1837-1843, 1997
16. de Wit R, Stoter G, Sleijfer DT, et al: Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: A randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group - European Organization for Research and Treatment of Cancer. Br J Cancer 78:828-832, 1998
17. Kuczmarski RJ, Flegal KM, Campbell SM, et al: Increasing prevalence of overweight among US adults: The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA 272:205-211, 1994
18. Schlant RC, Blomqvist CG, Brandenburg RO, et al: Guidelines for exercise testing: A report of the Joint American College of Cardiology/American Heart Association Task Force on Assessment of Cardiovascular Procedures (Subcommittee on Exercise Testing). Circulation 74:653A-667A, 1986
19. Berman DS, Kiat H, Maddahi J: The new 99mTc myocardial perfusion imaging agents: 99mTc-sestamibi and 99mTc-teboroxime. Circulation 84:17-21, 1991 (suppl)
20. Cohen GI, Pietrolungo JF, Thomas JD, et al: A practical guide to assessment of ventricular diastolic function using Doppler echocardiography. J Am Coll Cardiol 27:1753-1760, 1996
21. Badano L, Stoian J, Cervesato E, et al: Reproducibility of wall motion score and its correlation with left ventricular ejection fraction in patients with acute myocardial infarction. Am J Cardiol 78:855-858, 1996
22. Koren MJ, Devereux RB, Casale PN, et al: Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 114:345-352, 1991
23. Albers JJ, Warnick GR, Wiebe D, et al: Multi-laboratory comparison of three heparin-Mn2+ precipitation procedures for estimating cholesterol in high-density lipoprotein. Clin Chem 24:853-856, 1978
24. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502, 1972
25. National Cholesterol Education Program: Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 89:1333-1445, 1994
26. Pedrinelli R, Giampietro O, Carmassi F, et al: Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 344:14-18, 1994
27. Parving HH: Microalbuminuria in essential hypertension and diabetes mellitus. J Hypertens Suppl 14:S89-S93, 1996
28. Hansen SW, Berthelsen JG, von der Maase H: Long-term fertility and Leydig cell function in patients treated for germ cell cancer with cisplatin, vinblastine, and bleomycin versus surveillance. J Clin Oncol 8:1695-1698, 1990
29. Caro JF: Clinical review 26: Insulin resistance in obese and nonobese man. J Clin Endocrinol Metab 73:691-695, 1991
30. Pearson ES, Hartley HO: Biometrika Tables for Statisticians (ed 3). London, United Kingdom, Biometrika Trust, 1976
31. Einhorn LH, Williams SD, Loehrer PJ, et al: Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: A Southeastern Cancer Study Group protocol. J Clin Oncol 7:387-391, 1989
32. Levi JA, Thomson D, Sandeman T, et al: A prospective study of cisplatin-based combination chemotherapy in advanced germ cell malignancy: Role of maintenance and long-term follow-up. J Clin Oncol 6:1154-1160, 1988
33. Samson MK, Rivkin SE, Jones SE, et al: Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer: A Southwest Oncology Group study. Cancer 53:1029-1035, 1984
34. Stoter G, Sleijfer DT, ten Bokkel Huinink H, et al: High-dose versus low-dose vinblastine in cisplatin-vinblastine-bleomycin combination chemotherapy of non-seminomatous testicular cancer: A randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 4:1199-1206, 1986
35. Bosl GJ, Gluckman R, Geller NL, et al: VAB-6: An effective chemotherapy regimen for patients with germ-cell tumors. J Clin Oncol 4:1493-1499, 1986
36. Bosl GJ, Geller NL, Vogelzang NJ, et al: Alternating cycles of etoposide plus cisplatin and VAB-6 in the treatment of poor-risk patients with germ cell tumors. J Clin Oncol 5:436-440, 1987
37. Reynolds TF, Vugrin D, Cvitkovic E, et al: VAB-3 combination chemotherapy of metastatic testicular cancer. Cancer 48:888-898, 1981
38. Logothetis CJ, Samuels ML, Selig DE, et al: Cyclic chemotherapy with cyclophosphamide, doxorubicin, and cisplatin plus vinblastine and bleomycin in advanced germinal tumors: Results with 100 patients. Am J Med 81:219-228, 1986
39. Nichols CR, Roth BJ, Williams SD, et al: No evidence of acute cardiovascular complications of chemotherapy for testicular cancer: An analysis of the Testicular Cancer Intergroup Study. J Clin Oncol 10:760-765, 1992
40. Williams SD, Birch R, Einhorn LH, et al: Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316:1435-1440, 1987
41. Nichols CR, Williams SD, Loehrer PJ, et al: Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: A Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 9:1163-1172, 1991
42. Roth BJ, Greist A, Kubilis PS, et al: Cisplatin-based combination chemotherapy for disseminated germ cell tumors: Long-term follow-up. J Clin Oncol 6:1239-1247, 1988
43. Sagie A, Benjamin EJ, Galderisi M, et al: Echocardiographic assessment of left ventricular structure and diastolic filling in elderly subjects with borderline isolated systolic hypertension (the Framingham Heart Study). Am J Cardiol 72:662-665, 1993
44. Vanoverschelde JL, Wijns W, Michel X, et al: Asynchronous (segmental early) relaxation impairs left ventricular filling in patients with coronary artery disease and normal systolic function. J Am Coll Cardiol 18:1251-1258, 1991
45. Zarich SW, Arbuckle BE, Cohen LR, et al: Diastolic abnormalities in young asymptomatic diabetic patients assessed by pulsed Doppler echocardiography. J Am Coll Cardiol 12:114-120, 1988
46. Levy D, Garrison RJ, Savage DD, et al: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322:1561-1566, 1990
47. Ghali JK, Liao Y, Simmons B, et al: The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med 117:831-836, 1992
48. Vogelzang NJ, Bosl GJ, Johnson K, et al: Raynaud's phenomenon: A common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med 95:288-292, 1981
49. Yudkin JS, Forrest RD, Jackson CA: Microalbuminuria as predictor of vascular disease in non-diabetic subjects: Islington Diabetes Survey. Lancet 2:530-533, 1988
50. Damsgaard EM, Froland A, Jorgensen OD, et al: Microalbuminuria as predictor of increased mortality in elderly people. BMJ 300:297-300, 1990
51. Berger CC, Bokemeyer C, Schuppert F, et al: Endocrinological late effects after chemotherapy for testicular cancer. Br J Cancer 73:1108-1114, 1996
52. Bosl GJ, Bajorunas D: Pituitary and testicular hormonal function after treatment for germ cell tumours. Int J Androl 10:381-384, 1987
53. Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
54. Travis LB, Curtis RE, Storm H, et al: Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 89:1429-1439, 1997